MEK1 (S218D,S222D)-pcw107 Citations (3)

Originally described in: Systematic identification of signaling pathways with potential to confer anticancer drug resistance.
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877. PubMed Journal

---

Articles Citing MEK1 (S218D,S222D)-pcw107

Articles
Gain-of-function hot spot mutant p53(R248Q) regulation of integrin/FAK/ERK signaling in esophageal squamous cell carcinoma. Yu VZ, So SS, Lung ML. Transl Oncol. 2021 Jan;14(1):100982. doi: 10.1016/j.tranon.2020.100982. Epub 2020 Dec 11. PubMed
The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis. Kobelt D, Perez-Hernandez D, Fleuter C, Dahlmann M, Zincke F, Smith J, Migotti R, Popp O, Burock S, Walther W, Dittmar G, Mertins P, Stein U. Oncogene. 2021 Aug;40(34):5286-5301. doi: 10.1038/s41388-021-01917-z. Epub 2021 Jul 10. PubMed
Molecular control of cell density-mediated exit to quiescence. Fan Y, Meyer T. Cell Rep. 2021 Jul 27;36(4):109436. doi: 10.1016/j.celrep.2021.109436. PubMed

If you have published an article using this material, please email us at to have your article added to this page.